Aclaris Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Aclaris reported Q2 2026 net loss of $21.5M (vs. $15.4M YoY); cash/securities of $170.6M as of June 30, 2026, plus $40.2M raised post-quarter via 7.3M share ATM offering at Leerink/Cantor Fitzgerald. Pipeline: ATI-052 bispecific antibody showed positive Phase 1a SAD/MAD results supporting quarterly dosing potential; Phase 1b POC trials in asthma and atopic dermatitis on track for H2 2026 readout; Phase 2b initiation planned Q4 2026. Bosakitug Phase 2 (109 AD patients) enrollment complete, Q4 2026 readout expected. Company states cash sufficient through end of 2028 without additional financing.
Why this rating
Positive clinical data (Phase 1a ATI-052) and 2.5yr cash runway are modest positives for a $149M-cap biotech; however, early stage (Phase 1b), dilutive 7.3M share raise (~5% dilution), and rising burn ($41.3M H1 2026 loss vs. $30.5M YoY) offset gains. Moderate news, not trajectory-changing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.